title: GALECTIN-3 AS A PROGNOSTIC BIOMARKER IN PATIENTS WITH NON-HODGKIN LYMPHOMA.
abstract: The aim of the study - to evaluate the prognostic value of galectin-3 for cumulative survival in patients with controlled non-Hodgkin lymphoma. Eighty two out subjects with full or partial remission of non-Hodgkin lymphoma were enrolled in the study. Observation period was up to 12 months. Blood samples for biomarkers measurements were collected. ELISA method for measurements of circulating level of Gal-3 and NT-pro-brain natriuretic peptide (NT-proBNP) was used. Hemodynamic evaluation was performed by transthoracic echocardiography. Fifty five cumulative clinical events occurred in 21 patients (25.6%) within the follow-up, with their distribution being as follows: 5 cardiovascular deaths, 24 cardiac arrhythmias, 8 cardiac ischemic events, 3 strokes, 9 chronic heart failures and 6 hospital admissions for cardiovascular reasons. Circulating levels of Gal-3 in subjects without and with cardiovascular events were 5.37 ng/ml (95% confidence interval [CI]=2.90-7.85 ng/ml) and 13.97 ng/ml (95% CI=7.82-20.11 ng/ml) (P=0.03) respectively. The results of regression analysis showed directly related circulating Gal-3 with E/Em (r=0.45, P=0.045), T2DM (r=0.38, P=0.01). Multivariate logistic regression revealed independent predictive value of circulating Gal-3 for 12 months cumulative cardiovascular events (odds ratio [OR]=1.11; 95% CI=1.05-1.25; P=0.005). In fact, Gal-3, NT-pro-BNP, GFR, and LVEF remained statistically significant predictors for cumulative cardiovascular events, whereas T2DM, hypertension, obesity did not. Increased circulating Gal-3 associates with increased 12 months cumulative cardiovascular events among patients with documented non-Hodgkin lymphoma.
authors.affiliation: Zaporozhye State Medical University, Ukraine.
authors.forename: B
authors.initials: B
authors.lastname: Samura
mesh_terms: D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000097:blood / Q000175:diagnosis* / Q000401:mortality; D015415:Biomarkers / Q000097:blood; D001798:Blood Proteins; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D004452:Echocardiography; D005260:Female; D037502:Galectin 3 / Q000097:blood*; D037161:Galectins; D005919:Glomerular Filtration Rate / Q000502:physiology; D006333:Heart Failure / Q000097:blood / Q000175:diagnosis* / Q000401:mortality; D006439:Hemodynamics / Q000502:physiology; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000097:blood / Q000175:diagnosis* / Q000188:drug therapy / Q000401:mortality; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000097:blood / Q000175:diagnosis* / Q000401:mortality; D020097:Natriuretic Peptide, Brain / Q000097:blood; D010446:Peptide Fragments / Q000097:blood; D011237:Predictive Value of Tests; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis; D011446:Prospective Studies; D012074:Remission Induction; D000069283:Rituximab; D020521:Stroke / Q000097:blood / Q000175:diagnosis* / Q000401:mortality; D016019:Survival Analysis; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D015415:Biomarkers; D001798:Blood Proteins; D037502:Galectin 3; D037161:Galectins; C428445:LGALS3 protein, human; D010446:Peptide Fragments; C571759:R-CHOP protocol; C109794:pro-brain natriuretic peptide (1-76); D020097:Natriuretic Peptide, Brain; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone